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Abstract
Purpose We aimed to compare the preventive effect of 5-day
administration of aprepitant with single administration of
fosaprepitant meglumine against nausea and vomiting symp-
toms due to highly emetogenic chemotherapy regimens com-
prising cisplatin (CDDP).
Methods Subjects were inpatients who underwent chemother-
apy for gastric cancer, esophageal cancer, lung cancer, or head
and neck cancer with a regimen comprising 60mg/m2 or higher
dose of CDDP. In this randomised, open-label, controlled
study, the subjects were assigned to a group given aprepitant
for 5 days or a group given a single administration of
fosaprepitant meglumine. The nausea and vomiting symptoms
that emerged within 7 days after the first CDDP administration
were investigated with a questionnaire form; the results were
compared between the two groups. Risk factors affecting nau-
sea and vomiting symptoms were also investigated.
Results Of the 101 patients enrolled, 93 patients were
included (48 in the 5-day aprepitant group and 45 in
the single fosaprepitant meglumine group). No signifi-
cant intergroup differences in the complete response rate
or the complete control rate were found over the entire
period. The nausea score tended to increase from day 3
in both groups, but no significant intergroup difference
was observed. Furthermore, the investigation of risk fac-
tors affecting moderate or severe nausea symptoms in-
dicated that the fosaprepitant meglumine administration
was not a risk factor.
Conclusions Single administration of fosaprepitant
meglumine was not inferior to 5-day administration of
aprepitant for preventing acute and delayed nausea and
vomiting symptoms occurring after administration of
CDDP (60 mg/m2 or higher).
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Introduction
Chemotherapy-induced nausea and vomiting (CINV) necessi-
tates modifications to the regimen in severe cases and is re-
portedly a factor affecting the prognosis of cancer treatment
[1, 2]. CINV reduced the amount of food intake, resulting in
malnutrition, body weight loss and reduced performance sta-
tus (PS) [3]. The reduced PS leads to an increased incidence of
haematotoxicity [4]. Therefore, it is critical to prevent CINV.
The emetogenicity of anti-cancer agents has been categorised
according to their risk levels in guidelines by theMultinational
Association of Supportive Care in Cancer (MASCC) [5], the
American Society of Clinical Oncology (ASCO) [6] and the
National Comprehensive Cancer Network (NCCN) [7]. In all
of these guidelines, cisplatin (CDDP) is classified as a highly
emetogenic agent [8, 9]. Appropriate measures against CINV
are essential in CDDP administration. In addition, CDDP is
characterised by a biphasic emergence of CINV in the acute
(within 24 h after starting the administration) and late phases
(beyond 24 h after starting the administration) [10].
The development of antiemetic drugs has been remarkable;
selective 5-HT3 receptor antagonists were developed in the
1990s. Ohmatsu et al. have reported that the granisetron+
dexamethasone group fared better than the metoclopramide+
dexamethasone group with respect to the prevention of CINV
during CDDP administration [11]. Thereafter, it has been
shown that the NK-1 receptor is closely involved in CINV
[12], and substance P induces vomiting through binding to
the NK-1 receptor in the central nervous system [13–15]. The
NK-1 receptor has also been noted as a new target for antiemet-
ic therapy [16]. NK-1 receptor antagonist, aprepitant, has been
developed and was listed in the NCCN guidelines in 2004.
Aprepitant is an anti-emetic agent with a novel mechanism of
action. It inhibits the binding of substance P to the NK-1 recep-
tor in the central nervous system [17, 18] and reduces the inci-
dence of acute and delayed nausea and vomiting symptoms
significantly when used in combination with the conventional
anti-emetic therapy (concomitant use of ondansetron and dexa-
methasone) [19]. Aprepitant has also been listed in the drug
price standard in Japan since December 2009 and accordingly
included as an effective anti-emetic that is also used for delayed
emesis in ‘Guidelines for Proper Use of Anti-emetics Version
1’, which was created by the Japan Society of Clinical Oncol-
ogy in May 2010. Subsequently, fosaprepitant meglumine, a
phosphorylated prodrug of aprepitant with improved water sol-
ubility, was developed.
The non-inferiority of fosaprepitant meglumine to
aprepitant in the anti-emetic effect in the acute and late phases
has been demonstrated in a phase III study conducted in 27
countries to compare aprepitant administered for 3 days and
fosaprepitant meglumine administered once in patients receiv-
ing the highly emetogenic anti-cancer agent CDDP (≥70 mg/
m2) [20]. Based on this result, fosaprepitant meglumine has
been listed in the NCCN guidelines since 2011 and also in-
cluded in the Japanese drug price standard in November 2011.
Thereafter, a phase III clinical study in Japanese patients treat-
ed with CDDP (≥70 mg/m2) [21] was conducted and demon-
strated a superior effect in the fosaprepitant meglumine group
compared to that of the placebo group. However, no studies
have been conducted to directly compare the anti-emetic effect
of aprepitant with fosaprepitant meglumine in Japanese pa-
tients. Moreover, although guidelines released by the Japan
Society of Clinical Oncology have recommended 3 days of
aprepitant administration, a domestic phase II clinical trial
targeting Japanese subjects [22] has verified a 5-day adminis-
tration of aprepitant. This is because aprepitant was developed
in Japan as a drug that should be administered for 5 days.
However, the overseas clinical trials [19, 23, 24] tested the
3-day regimen of aprepitant, and the NCCN guidelines [7]
recommended the 3-day technique. Therefore, after carefully
considering the domestic phase II clinical trial results, the
Ministry of Health, Labour and Welfare in Japan decided that
sufficient efficacy could be anticipated with 3-day aprepitant
administration for Japanese patients and that up to 5 days of
administration would be acceptable. In light of the above
facts, we decided that it was necessary to compare the 5-day
administration of aprepitant and a single administration of
fosaprepitant meglumine to compare the efficacy of aprepitant
and fosaprepitant meglumine in Japanese patients who had
received CDDP, a highly-emetic anticancer agent. Moreover,
a phase III trial [20] that compared the 3-day administration of
aprepitant and the single administration of fosaprepitant
meglumine compared antiemetic effects until 5 days after
CDDP administration; however, this study did not examine
the subsequent progress of the patients. Therefore, we evalu-
ated the degree of nausea and vomiting symptoms until day 7
in Japanese patients who underwent chemotherapy with
CDDP at Fujita Health University Hospital (the day of CDDP
administration was day 1) to prospectively compare the effects
on nausea and vomiting symptoms in a 5-day aprepitant ad-




In this study, we enrolled Japanese patients who started to
receive chemotherapy comprising CDDP (≥60 mg/m2) for
lung cancer, gastric cancer, esophageal cancer, or head and
neck cancer between January 2013 and March 2014 at the
Fujita Health University Hospital. They provided consent to
participate in this study after the intent of the study was ex-
plained to them. However, any patient who had nausea or
vomiting within 24 h before starting administration of anti-
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neoplastic drugs, who could not receive a drug orally, who
could not answer the questionnaire, who did not provide con-
sent or who was considered unsuitable to this study was
excluded.
Investigations
An equal number of subjects were randomly assigned to the
aprepitant treatment group (group A; aprepitant, a 5-HT3 re-
ceptor antagonist and dexamethasone) and the fosaprepitant
meglumine treatment group (group B; fosaprepitant
meglumine, a 5-HT3 receptor antagonist and dexamethasone).
Anti-emetic agents were used in both groups in accordance
with the dosage instruction on the package inserts. Specifical-
ly, in group A, aprepitant was administered at 125 mg on day 1
(the day administration of anti-neoplastic agents started) and
at 80 mg daily on days 2–5, and a 5-HT3 receptor antagonist
(palonosetron [0.75 mg], granisetron [3 mg] or azasetron
[10 mg]) was administered, along with 6.6–9.9 mg of dexa-
methasone on day 1 and 3.3–6.6 mg daily on days 2–4. Group
B subjects received fosaprepitant meglumine at 150 mg on
day 1, 6.6–9.9 mg of dexamethasone on day 1 and 3.3–
6.6 mg daily on days 2–4, and a 5-HT3 receptor antagonist
(palonosetron [0.75 mg], granisetron [3 mg] or azasetron
[10 mg]).
Assessment
To survey the occurrence of nausea and vomiting, we prepared
a nausea/vomiting recording form (Fig. 1) based on the MAT
(questionnaire about nausea and vomiting), which was devel-
oped by the Multinational Association of Supportive Care in
Cancer (MASCC). Investigators interviewed their patients
daily about states of nausea and vomiting symptoms from
day 1 (the day CDDPwas administered) to day 7 and recorded
the responses. Based on a report from Longo et al. [25], we
conducted patient interviews only for the first course to min-
imise bias. Nausea symptoms were surveyed and recorded by
a pharmacist according to the numeric rating scale (NRS; 11-
point scale, in which 0 represents a condition without nausea
and 10 represents a condition with the worst conceivable nau-
sea). The results were then categorised according to the Likert
scale into ‘no symptom or mild’ (NRS, 0–2), ‘moderate’ (3–6)
and ‘severe’ (7–10). For vomiting symptoms, the number of
times vomiting (including dry vomiting) occurred was sur-
veyed every day and evaluated according to the National Can-
cer Institute-Common Terminology Criteria for Adverse
Events Version 4.0 (NCI-CTCAE ver. 4.0). With regard to
the effects of the drugs on nausea and vomiting, the proportion
of the patients who did not experience vomiting or dry
vomiting (the complete response [CR] rate) and the proportion
of the patients who did not experience vomiting or dry
vomiting and had ‘no symptom or mild’ nausea (the complete
control [CC] rate) were determined and compared between the
two groups. We also investigated age, sex, cancer type, ad-
ministration of concomitant radiotherapy and use of opioid as
potential confounding factors. We also examined susceptibil-
ity to motion sickness, history of alcohol consumption and
history of pregnancy, which were proposed as risk factors
for nausea and vomiting by Koeller et al. [26].
Statistical analysis
Continuous variables in patient background data were
expressed as mean±SD, and intergroup comparison was per-
formed with an unpaired t test. Patient background data com-
posed of a nominal scale was expressed in %, and χ2 test was
used for intergroup comparisons. χ2 test was used to compare
the CR and CC rates between the two groups. The nausea
score was expressed in a form of median (first quartile–third
quartile), and changes in the score over time were compared
with the Friedman test, followed by multiple comparisons
with the Wilcoxon signed-rank test with Bonferroni correc-
tion. Intergroup comparisons were performed with the two-
way repeated measures analysis of variance. To explore the
risk factors for nausea and vomiting, univariate analysis was
performed, and then multivariate logistic regression analysis
was performed on items with a significance level less than
10 %. The analysis software used was SPSS Ver. 22.0 (IBM
Corporation, Armonk, NY, USA); the significance level used
was less than 5 %.
Statement of ethics
This study was conducted in compliance with the ‘Ethical
Guidelines for Clinical Research’ with an approval from the




Of 101 patients enrolled, 8 patients were excluded as per the
exclusion criteria, and the remaining 93 patients were
randomised: 48 in group A and 45 in group B. The patient
inclusion flowchart is presented in Fig. 2. No differences were
noted in the patient background between the two groups
(Table 1).
Efficacy
The CR rates in the acute phase (days 1 and 2), the first stage
of the late phase (days 3–5) and the second stage of the late
phase (days 6 and 7) were separately compared between group
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A and group B. The CR rates in group A and group B were,
respectively, 97.9 and 97.8 % for the acute phase (P=0.96),
87.5 and 84.4 % for the first stage of the late phase (P=0.67)
and 89.6 and 90.0 % for the second stage of the late
phase (P=0.91), showing no significant differences be-
tween the two groups in all phases (Fig. 3a). The CR
rate for the entire period was 85.4 % (41/48) in group
A and 82.2 % (37/45) in group B, also showing no
significant difference (P=0.90). While comparing the
CR rate between the acute and late phases in group
A, no significant differences were found between the
acute phase and the first stage (P=0.36) or the second
stage of the late phase (P=0.63). The CR rate was sim-
ilarly compared between the phases also in group B, but
no significant differences were found between the acute
phase and the first stage (P=0.19) or the second stage
of the late phase (P=0.60).
The CC rate was also separately compared between the two
groups. The CC rates in group A and group B were, respec-
tively, 77.1 and 91.1 % for the acute phase (P=0.066), 60.4
and 73.3 % for the first stage of the late phase (P=0.19), and
66.7 and 71.1 % for the second stage of the late phase (P=
0.64). Although differences between the two groups were not
of statistical significance in any phases, the CC rate in group A
Fig. 1 Nausea/vomiting
recording form
Fig. 2 Study flow chart
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tended to be slightly lower in the acute phase (Fig. 3b). The
CC rate for the entire period also did not differ significantly
between group A (60.4 %, 29/48) and group B (64.4 %, 29/
45) (P=0.85). Comparisons of the CC rate between the acute
and late phases in group A showed no significant differences
between the acute phase and the first stage (P=0.23) or the
second stage of the late phase (P=0.78). Similar phase-to-
phase comparisons of the CC rate in group B also showed
no significant differences between the acute phase and the first
stage (P=0.16) or the second stage of the late phase
(P=0.093).
For day-to-day changes in the nausea score, while a
significant consecutive increase was observed from day
3 to day 7 in group A, the score increased only on days
3 and 4 in group B. However, no significant differences
were detected by the two-way repeated measures analy-
sis of variance (Table 2).
Risk factors
Risk factors for moderate or severe nausea symptoms were
investigated. The two factors ‘age’ and ‘susceptible to motion
sickness’ were of near statistical significance in the univariate
analysis, but the multivariate analysis indicated that neither
was a risk factor (Table 3).
Table 1 Patient background
Group A (n=48) Group B (n=45) P value
Age (years) 61.7±11.7 65.4±10.0 0.099
Male, Female 40,8 34,11 0.35
CDDP (mg/m2) 70 (60–80) 70 (60–80) 0.61
Cancer type 0.85
Lung cancer 14 12
Gastric cancer 15 10
Esophageal cancer 7 9
Head and neck cancer 11 13
Unknown primary 1 1
RT concomitantly used 23 21 0.90
Opioid concomitantly used 3 3 0.93
Alcohol consumption 29 26 0.80
Susceptible to motion sickness 3 6 0.25
History of emesis due to pregnancy 3 7 0.51
5-HT3 receptor antagonist 0.93
Palonosetron 23 22
Other than palonosetron (granisetron or azasetron) 25 23
CDDP cisplatin, RT radiotherapy
Fig. 3 Comparison of the CR
and CC rates between group A
and group B
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Discussion
For acute and delayed vomiting symptoms seen after CDDP-
based chemotherapy, no difference in incidence was found
between the 5-day aprepitant administration group and the
single fosaprepitant meglumine administration group.
Grunberg et al. compared the CR rate between the 3-day
aprepitant administration group and the single fosaprepitant
meglumine administration group of patients treated with at
least 70 mg/m2 of CDDP and reported no significant inter-
group differences in the acute phase (88.0 and 89.0 %, respec-
tively) or the late phase (74.2 and 74.3 %). Although this
result was in agreement with that of our study, Grunberg
et al. used a higher CDDP dose and administered aprepitant
for 3 days rather than 5 days [20]. These differences in condi-
tions may underlie a lower CR rate observed in their study
than that in our study. While a phase II study in Japanese
patients treated with CDDP (≥70 mg/m2) showed that the
CR rate in the 5-day aprepitant administration group was
higher than that of the placebo group [22], the CR rate for
the entire study period in the 5-day aprepitant administration
group was 70.5 %, which was lower than the rate obtained in
our study. This difference may be attributable to the difference
in the CDDP dose between the two studies. In this study, we
intentionally chose a CDDP dose of ≥60 mg/m2 for the fol-
lowing reason; in the Japanese gastric cancer guidelines, the
first-line drug therapy options include combination therapy
with CDDP (60 mg/m2) and S-1 (80 mg/m2) [27], and we
thought that patients with gastric cancer, for which CDDP is
a first choice, should be included in CDDP studies about Jap-
anese subjects. In the present study, the CDDP dose did not
differ between the two groups, and it is highly unlikely that the
results were affected by the difference in the CDDP dose.
Daily changes in the CC rate and nausea score were inves-
tigated, but neither showed significant differences between the
two groups. Furthermore, the result from the logistic regres-
sion analysis of risk factors for nausea of moderate or higher
severity indicated that fosaprepitant meglumine administra-
tion was not a risk factor. From these results, the nausea-
suppressing effect of fosaprepitant meglumine administered
Table 2 Daily changes in nausea score in group A and group B
Group A Group B
Day 1 0 (0–0) 0 (0–0)
Day 2 0 (0–1) 0 (0–0)
Day 3 0 (0–3)* 0 (0–1)*
Day 4 1 (0–3)**, *** 0 (0–2)*
Day 5 1 (0–3)**, *** 0 (0–2)
Day 6 0 (0–3)** 0 (0–2)
Day 7 0 (0–3)** 0 (0–2)
P value (Friedman test) 0.0013 0.0013
*P<0.05; **P<0.01 versus day 1; ***P<0.05 versus day 2 (Wilcoxon’s
signed-rank test followed by Bonferroni correction), P=0.658 (two-way
repeated measures analysis of variance)
Table 3 Risk factors for
moderate or severe nausea
symptoms
Univariate analysis Multivariate analysis
Odds ratio (95 % CI) P value Odds ratio (95 % CI) P value
Administration of fosaprepitant 0.84 0.69
(0.36–1.95)




CDDP (mg/m2) 1.02 0.24
(0.98–1.06)
Treatment with RT 1.08 0.85
(0.47–2.51)
Concomitant use of opioid 1.72 0.52
(0.33–9.03)
Alcohol consumption 0.67 0.37
(0.29–1.58)
Susceptible to motion sickness 3.79 0.073 2.77 0.20
(0.88–16.30) (0.59–12.96)
Administration of palonosetron 1.01 0.98
(0.44–2.34)
CDDP cisplatin, RT radiotheraphy
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once was found non-inferior to that of aprepitant administered
for 5 days. In studies on the effect of aprepitant or
fosaprepitant meglumine in CDDP-treated patients, the CR
and CC rates have been used often, but the results have been
based on the rate determined for a certain period [18–21]
rather than the rate changes followed over the course of the
study. While a visual analog scale [19–20] and other scoring
systems [21] are generally used to evaluate the nausea symp-
tom, we used the interview survey of patients with NRS for
detailed, daily evaluation of the symptom. The demonstration
of the absence of intergroup differences, even when changes
in the nausea symptom were investigated in detail with
NRS, provides a more solid support for the prophylactic
equivalence of the two agents. In the study conducted
by Grunberg et al . to compare aprepi tant and
fosaprepitant meglumine, the anti-emetic effect was not
investigated beyond 5 days after the CDDP administra-
tion. In contrast, our present study suggested that the
anti-CINV effect of fosaprepitant meglumine persisted
over 7 days after the single administration. This is a
new and very intriguing finding.
Sekine et al. searched for risk factors that affected the inci-
dence of CINV in multiple clinical studies conducted with
chemotherapy-naïve patients in Japan and reported that the
risk factors include female gender, less advanced age (less
than 55 years) and no history of alcohol consumption. The
risk of CINVemergence increases as the number of applicable
risk factors increases [28]. However, our present investigation
of risk factors for moderate or severe nausea indicated that no
factors were influential. Moreover, the two groups were com-
parable in the number of risk factors: Patients with 1, 2 and 3
risk factors were, respectively, 20 (41.7 %), 7 (14.6 %) and 2
(4.2 %) in group A and 14 (31.1 %), 8 (17.8 %) and 2 (4.4 %)
in group B. The risk factors reported by Sekine et al. were thus
considered highly unlikely to have affected the results of the
present study. In addition to aprepitant and fosaprepitant
meglumine, the subjects in this study received another anti-
emetic selected from granisetron, azasetron and palonosetron.
While granisetron and azasetron reportedly are as potent as
ondansetron in terms of the anti-emetic effect [29–31], Hashi-
moto et al. [32] reported that the CR rate in patients treated
with a highly emetic regimen comprising CDDP at a
dose of 50 mg/m2 or higher tended to be lower in the
granisetron group than in the palonosetron group (59.1
versus 65.7 %; P=0.0539). Based on this result,
palonosetron administration was included as a variable
in our risk factor analysis but was found uninfluential.
This may be due to some differences in study condi-
tions, but details remain unknown.
In Japanese patients treated with CDDP+5-FU (CDDP
80 mg/m2 on day 1+5-FU 800 mg/m2 on days 1–5) for head
and neck cancer, Aoki et al. [33] investigated the nausea and
vomiting symptoms over an observation period of 7 days from
the start of chemotherapy (days 1–7) in the 3-day and the 5-
day aprepitant administration group. They reported that the
effect was maintained for 7 days in the 5-day group, while
the effect declined from day 6 onwards in the 3-day group. In
the present study, we compared the CR and CC rates between
the acute phase and the first and second stages of the late phase
but did not find any apparent decline of the effect in the single
fosaprepitant meglumine administration group or the 5-day
aprepitant administration group. Although conditions were
not identical, results from our present study corroborated the
results obtained by Aoki et al., suggesting that single admin-
istration of fosaprepitant meglumine was non-inferior to the 5-
day administration of aprepitant in terms of persistence
of the effect.
Conclusions
The single administration of fosaprepitant meglumine was as
effective as the 5-day administration of aprepitant for
preventing acute and delayed nausea and vomiting symptoms
occurring after the administration of CDDP (≥60 mg/m2).
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